secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adicet Bio, Inc. (ACET)
CIK:        0001720580
Form:       8-K
Filed at:   2024-06-05T23:59:59+00:00
Accession:  0000950170-24-069067
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adicet Bio gets FDA Fast Track for ADI-001 in lupus nephritis; Phase 1 starts this month
--------------------------------------------------------------------------------

- FDA granted Fast Track Designation for ADI-001 in relapsed/refractory class III or IV lupus nephritis.
- Company plans to initiate Phase 1 clinical study in lupus nephritis in June 2024.
- ADI-001 previously showed CD19+ B-cell depletion in non-Hodgkin's lymphoma, similar to CAR T data in autoimmune diseases.
- CEO Chen Schor cites urgent unmet need and plans to expand autoimmune program beyond lupus nephritis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720580/000095017024069067/0000950170-24-069067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720580/000095017024069067/acet-20240605.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-069067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer